Francesco Marincola, Kite global head of cell therapy research
Gilead presses forward with next-gen CAR-T, inking deal with small synthetic biology startup
Gilead is dipping its toes into some early-stage discovery work.
Through its subsidiary Kite Pharma, Gilead signed a deal with California biotech Refuge Biotechnologies to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
